Pomalidomide and Myeloma Meningitis

Leukemia and Lymphoma - United Kingdom
doi 10.3109/10428194.2012.723708
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

Orphan Designation: Pomalidomide, Treatment of Multiple Myeloma

Case Medical Research
2019English

Bendamustine, Pomalidomide, and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma

Blood Cancer Journal
OncologyHematology
2018English

Review New Drugs in Multiple Myeloma – Role of Carfilzomib and Pomalidomide

Wspolczesna Onkologia
OncologyRadiologyNuclear MedicineImaging
2014English

Response to Salvage Therapies and Outcome in Patients With Multiple Myeloma Relapsing After Pomalidomide Therapy

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2011English

Daratumumab vs. Pomalidomide for the Treatment of Relapsed/Refractory Multiple Myeloma: A Cost‐effectiveness Analysis

American Journal of Hematology
Hematology
2018English

Genome-Wide Screening Reveals a Role for Subcellular Localization of CRBN in the Anti-Myeloma Activity of Pomalidomide

Scientific Reports
Multidisciplinary
2020English

Potent Antitumor Effect of Combination Therapy With Sub‑optimal Doses of Akt Inhibitors and Pomalidomide Plus Dexamethasone in Multiple Myeloma

Oncology Letters
Cancer ResearchOncology
2018English

Cost-Effectiveness of Pomalidomide, Carfilzomib, and Daratumumab for the Treatment of Patients With Heavily Pretreated Relapsed–refractory Multiple Myeloma in the United States

Clinical Therapeutics
Pharmacology
2017English

Pomalidomide Plus Low-Dose Dexamethasone Versus High-Dose Dexamethasone Alone for Patients With Relapsed and Refractory Multiple Myeloma (MM-003): A Randomised, Open-Label, Phase 3 Trial

The Lancet Oncology
Oncology
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy